Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Exelixis Inc.

|Includes: Exelixis, Inc. (EXEL)

Recent events inside EXEL have provided an extreme oversold condition. With 310 million in working capital, an impressive pipeline of compounds for multiple indications, numerous big pharma partners and recent insider buying ( CEO bought 30,000 and a Director just bought 100,000 shares). My short term target on EXEL is 4.50